FDA reviewers accept sugammadex data

In sugammadex from Merck & Co. Inc. (NYSE:MRK), agency reviewers said the company has resolved the agency's concerns over the integrity of hypersensitivity data and asked panelists to vote on

Read the full 308 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE